Transition From Buphenyl to RAVICTI for the Therapy of Byler Disease
NCT01949766 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2013-09-24
Summary
This is a single patient compassionate use protocol to determine whether RAVICTI will improve bile flow in a subject who previously tolerated therapy with Buphenyl.
Conditions
- Byler Disease
Interventions
- DRUG
-
Glycerol phenylbutyrate
Sponsors & Collaborators
-
University of Pittsburgh
lead OTHER
Eligibility
- Min Age
- 6 Months
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Study of Bile Acids in Patients With Peroxisomal Disorders
NCT00004442 ·Status: TERMINATED ·Phase: NA
-
Compassionate Use of Omegaven IV Fat Emulsion
NCT02477345 ·Status: NO_LONGER_AVAILABLE
-
The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy.
NCT01846806 ·Status: TERMINATED ·Phase: NA
-
Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET/CT
NCT01879735 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis
NCT00004441 ·Status: COMPLETED ·Phase: NA
-
Compassionate Use of Omegaven IV Fat Emulsion
NCT00816348 ·Status: TERMINATED ·Phase: PHASE2
-
Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Associated Hepatic Injury
NCT01412359 ·Status: APPROVED_FOR_MARKETING
-
Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease
NCT00004315 ·Status: UNKNOWN ·Phase: PHASE2
-
Effect of Bile Acids on the Secretion of Satiation Peptides in Humans
NCT01674946 ·Status: COMPLETED ·Phase: PHASE1
-
Obeticholic Acid in Bariatric and Gallstone Disease
NCT01625026 ·Status: COMPLETED ·Phase: PHASE2
-
Pancreatic Enzymes and Bile Acids in Acutely Ill Severely Malnourished Children
NCT04542473 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Compassionate Use of Omegaven® for the Treatment of Intestinal Failure Associated Liver Disease in Children
NCT02328768 ·Status: APPROVED_FOR_MARKETING
-
Bioavailability of Pancreatic Enzymes in the Human Upper Intestine (Duodenum and Jejunum)
NCT00749099 ·Status: TERMINATED ·Phase: NA
-
Pancreatic Enzyme Supplementation for Celiac Disease
NCT02475369 ·Status: TERMINATED ·Phase: PHASE4
-
Anti-inflammatory Therapy to Improve Outcomes After TPIAT
NCT02713997 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis
NCT00432861 ·Status: COMPLETED ·Phase: PHASE3
-
Phase III ALTU-135 CP Safety Trial
NCT00500084 ·Status: TERMINATED ·Phase: PHASE3
-
Intraductal Liposomal Bupivacaine for Chronic Pancreatitis
NCT04611958 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomy
NCT06121375 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)
NCT04336722 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
An Effectiveness, Safety, and Palatability Study of Pancrelipase Microtablets in Infants and Toddlers With Cystic Fibrosis and Fat Malabsorption
NCT00217204 ·Status: COMPLETED ·Phase: PHASE2
-
Regulation of Human Intestinal Bile Acid Transport in Health and Disease
NCT00018681 ·Status: COMPLETED
-
Compassionate Use of Omegaven to Reverse Parenteral Nutrition Induced Cholestasis
NCT01173159 ·Status: COMPLETED ·Phase: NA
-
Compassionate Use of IV Fish Oil for Parenteral Nutrition (PN) Liver Injury
NCT01425567 ·Status: APPROVED_FOR_MARKETING
-
Use of Pancreatic Enzymes in Short Bowel Syndrome
NCT03097029 ·Status: COMPLETED ·Phase: PHASE2